Australia's most trusted
source of pharma news
Friday, 29 August 2025
Posted 26 August 2025 AM
Rare Cancers Australia has joined the growing pushback against the PBAC, expressing frustration and confusion over its failure to act on a multi-cancer funding model.
It follows a decision by the Committee to reject an application by MSD for a broad listing for all TGA-registered indications for its blockbuster drug Keytruda, pointing out the model would exclude some patients with rare cancers.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.